ALPHAMED PRESS IMAGE: THE TWO THERAPIES DEMONSTRATED SIMILAR MID-TERM SAFETY AND EFFICACY, WHILE EACH CELL THERAPY HAD ITS UNIQUE ADVANTAGES AND ARE RECOMMENDED FOR CERTAIN CONDITIONS: FOR EXAMPLE, PBMNCS FOR PATIENTS WITH 2 OR MORE CRITICAL ISCHEMIC LIMBS AND PCC’S FOR PATIENTS WITH SIGNIFICANT PAIN. CREDIT: ALPHAMED PRESS Durham, NC – Mid-term results of the...
